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Summary: The burden of vascular diseases is growing worldwide, as the population ages, prompting a call to action not only
in terms of awareness but also and most urgently in recognizing the need for vascular physicians, also called angiologists.
Vascular medicine views the vascular system (arteries, veins, and lymphatics) as a whole, unique, and independent entity
requiring specialized competencies. Vascular physicians offer a holistic and comprehensive approach to vascular patients
including provision of interventional procedures, management of a heterogeneous group of multi-morbid and frail patients
affected by multi-vessel diseases, and connecting different specialists in a multidisciplinary effort. Vascular medicine
practise varies across European countries. While it is a firmly accepted medical speciality in many European countries it is not
formally recognized by the European Union limiting adoption in the other countries. The lack of vascular physicians likely
accounts for inequality of care of vascular patients as compared for example to patients with heart disease and might
contribute to adverse outcomes and healthcare costs associated with vascular diseases. To move forward in the struggle to
provide efficient care for multimorbid poly-vascular patients, it is essential to establish vascular medicine programs in Europe
and worldwide. Important steps to achieve this goal include improving public awareness of vascular diseases, attain formal
recognition by the EU of angiology/vascular medicine as a medical specialty, creating specialized treatment guidelines, and to
harmonize vascular care in Europe.
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Introduction
Vascular diseases affecting arteries, veins, lymphatics, and
the microcirculation represent a large and growing health
burden throughout Europe. It is estimated that peripheral
artery disease (PAD) may affect more than 20% of elderly
people worldwide [1, 2] while venous thromboembolism
accounts for an incidence of 104–183 per 100,000 person
years (similar to stroke) [3]. Further, one out of three suf-
fers from venous insufficiency, and approximately 140 to
250 million people worldwide have lymphedema, which
is still largely underestimated. The burden of vascular dis-
eases is estimated to grow worldwide, as the population
ages, prompting a call to action not only in terms of aware-
ness but also and most urgently in recognizing the need for
vascular physicians, also called angiologists. In order to
offer a holistic and comprehensive approach to vascular
patients, vascular physicians need to be able to manage a
heterogeneous group of multi-morbid and frail patients
affected by multi-vessel diseases, and to connect different
specialists including vascular surgeons, radiologists, cardi-
ologists, dermatologists, and diabetologists in a multidisci-
plinary effort. There is a compelling medical need to avoid
further fragmentation and inequality of care, in vascular
patient management, which has been so frequently docu-
mented [4, 5]. This fragmentation is somewhat historically
based on differing national and even local practices, as a
result of the inability of other specialties to view the vascu-
lar system (arteries, veins, and lymphatics) as a whole,
unique, and independent organ requiring specialized com-
petencies [6, 7]. Recognizing the need to federate vascular
physicians and raise awareness on vascular diseases, the
European Society for Vascular Medicine (ESVM) was cre-
ated in 2012 bringing under the same umbrella vascular
physicians throughout Europe [8]. In several countries vas-
cular medical specialists are already established as a disci-
pline within internal medicine. Inmany European countries
they are called angiologists, and there the medical spe-
cialty is referred to as angiology (from the Greek word an-
gios meaning vessel and logos meaning study). Globally,
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however, they are mostly called vascular physicians, and
the medical speciality is vascular medicine. While angiol-
ogy and vascular medicine are synonyms [9], this differ-
ence in terminology contributes to a dispersion of
unifying vision and creates a certain confusion within the
health care community as well as within the population at
large limiting visibility of this speciality. This issue needs
to be addressed at the European level.
Variability of vascular medicine practice
throughout Europe
Currently, the way patients with (multiple) vascular dis-
eases are managed is quite heterogeneous in Europe and
dispersed across multiple specialties. Vascular medicine
aims at integrating the care for the vascular system as a
whole and connecting the different professionals. Besides
vascular physicians, vascular surgeons, cardiologists, inter-
ventional radiologists, diabetologists, rheumatologists,
neurologists, and dermatologists play important roles in
the management of vascular patients, as do professions
allied tomedicine such as podiatrists, physiotherapists, vas-
cular nurses, and technologists. Depending on the country,
and even on local institutions, the role and contribution of
each specialty to the management of vascular patients vary
widely (Table I). While in central Europe’s countries, vascu-
lar physicians (deriving from internal medicine) play a
major role, in many others the vascular field is dominated,
or even monopolized, by general or vascular surgery. In
these central European countries, vascular physicians also
participate in the provision of effective endovascular treat-
ment of peripheral artery disease and progressively venous
disease (Table I). The development of vascular medicine is
often hampered by natural competition with other special-
ities, mainly in the area of endovascular therapy. The lack
of recognition of one vascular medicine specialty managing
vascular patients and coordinating the multidisciplinary
effort likely accounts for inequality of care of vascular
patients as compared for example to patients with heart
diseases and possibly contributes to high rates of adverse
events and healthcare costs associated with vascular
diseases.
Table I. Vascular medicine specialization in European countries.
Country Does vascular
medicine specialty
exist?
Specialization training requirements Who performs arterial endovascular procedures?
Austria yes 3 yrs internal medicine + 3 yrs vascular
medicine
Vascular physicians, interventional radiologists, vascular
surgeons
Belgium no Interventional radiologists, vascular surgeons, cardiologists
Czech Republic yes 5 yrs internal medicine/cardiology/
endocrinology + 2 yrs vascular
medicine
Vascular physicians, interventional radiologists
France yes 1 yr common with cardiologists + 3 yrs
dedicated vascular medicine
Interventional radiologists, vascular surgeons
Germany yes 3 yrs internal medicine + 3 yrs vascular
medicine
Vascular physicians, interventional radiologists, vascular
surgeons, cardiologists
Greece no Interventional radiologists, vascular surgeons, cardiologists
Hungary yes 5 yrs internal medicine + 2 yrs vascular
medicine
Vascular physicians, interventional radiologists, vascular
surgeons, cardiologists
Italy no Interventional radiologists, vascular surgeons, cardiologists
Ireland no Interventional radiologists, vascular surgeons
Netherlands yes 4 yrs internal medicine + 2 yrs vascular
medicine
Interventional radiologists, vascular surgeons, cardiologists
Poland yes Modular mode: 3 yrs internal medicine
+ 2 yrs vascular medicine or for
specialists in internal medicine or
vascular surgery: + 2 yrs vascular
medicine
Vascular physicians, interventional radiologists, vascular
surgeons
Romania (no) (Vascular diseases covered in
cardiology training; 6 yrs)
Cardiologists, radiologists, vascular surgeons
Serbia yes 5 yrs internal medicine + 1.5 yrs
vascular medicine
Vascular physicians, interventional radiologists, vascular
surgeons
Slovakia yes 2 yrs internal medicine + 3 yrs vascular
medicine
Vascular physicians, interventional radiologists
Slovenia yes 2 yrs internal medicine + 4 yrs
cardiology and vascular medicine
Vascular physicians, radiologists
Spain no Interventional radiologists, vascular surgeons
Sweden no Interventional radiologists, vascular surgeons, cardiologists
Switzerland yes 2 yrs internal medicine + 1 yr other + 3
yrs vascular medicine
Vascular physicians, interventional radiologists, vascular
surgeons
Ukraine no Vascular surgeons
United Kingdom Limited Ad-hominum accreditation as sub-
speciality of internal medicine
Interventional radiologists, vascular surgeons, (vascular
physicians)
Vasa (2019), 1–5 2019 Hogrefe
2 C. Heiss et al.,Medical vascular physicians in Europe
 
${
pro
toc
ol}
://e
co
nte
nt.
ho
gre
fe.
co
m/
do
i/p
df/
10
.10
24
/03
01
-15
26
/a0
00
81
0 -
 C
hri
sti
an
 H
eis
s <
c.h
eis
s@
su
rre
y.a
c.u
k>
 - F
rid
ay
, J
uly
 05
, 2
01
9 4
:56
:49
 A
M
 - I
P A
dd
res
s:1
31
.22
7.1
95
.85
 
The need for medical vascular physicians
The burden of aging multimorbid patients with several sig-
nificant vascular problems is rising worldwide [2]. German
secondary care data on PAD patients exemplify this show-
ing that prognosis of many vascular patients is as bad as
that of patients with Duke’s stage 2b colon cancer [10].
Almost half of the patients undergoing amputations did
not receive any vascular diagnostics within 2 years prior
to amputation and amputation accounts for a significant
proportion of healthcare costs [11, 12]. The situation is sim-
ilar, and may be even worse, in other countries. Overall,
mortality of PAD patients at 5 years is high and exceeds
that of some common cancers (Figure 1).
Further compared to coronary disease, the sub-optimal
management of vascular risk in these patients is well docu-
mented, resulting in an unacceptably high incidence of
myocardial infarction, stroke, and cardiovascular (CV)
death [13]. The REACH Registry [14] clearly linked CV
endpoints to poor risk management in these PAD patients,
and even within this past 12months publications show dis-
proportionate levels of fatal and non-fatal CV events in our
patients [14, 15]. Proper diagnostics, medical, and interven-
tional treatments as well as follow up, are a priority not only
for PAD patients, but also for patients affected by venous,
lymphatic, and microvascular disorders. Only a multidisci-
plinary approach with a strong medical basis can address
the problem. Thus, medical vascular physicians are needed
to face the medical need and connect specialties, to take
care of chronic disease, thus filling an important gap. How-
ever, the visibility of vascular medicine amongst the gen-
eral public and also among medical professionals is low.
Vascular medicine as a medical specialty
in Europe
The process for the European Union (EU) to include vascu-
lar medicine as a main specialty with automatic recognition
of doctor’s qualifications in all EU countries requires recog-
nition of the speciality in at least 2/5th of the member
states (article 25). While cardiology and vascular surgery
exist as medical specialties in all 28 and 25 EU countries,
respectively, vascular medicine is only accepted or formally
accredited by medical boards of 9 EU countries. Therefore,
vascular medicine is not listed as an individual specialty in
the EU document [16]. However, vascular medicine is a
firmly accepted medical speciality in 11 European coun-
tries, including Switzerland and Serbia. In addition, ad
hominem accreditation exists in the United Kingdom and
vascular medicine is taught and practised within other spe-
cialities e.g. in cardiology in Romania and Luxemburg
(Table I and Figure 2). The consequence of the lack of
EU recognition is inequality in patient care across Europe,
failure in recognizing vascular diseases as an independent
health burden, inability to set up comprehensive European
programs of awareness and prevention of vascular dis-
eases, and increase of health costs throughout Europe.
Another consequence is the lack of so called “automatic
recognition” process allowing vascular physicians to obtain
a medical license in one country based on their training and
practice as such in other countries. This seriously restricts
mobility of vascular physicians across Europe thereby
denying patients optimal care. The EU process permits 2
ways to include a “new” specialty onto the EU directive:
Figure 1. Relative 5-year PAD mortality rates [17] versus common cancers [10].
Figure 2. Landscape of Vascular medicine in Europe. EU countries
with nationally recognized vascular medicine specialty (green), ESVM
member countries without nationally recognized specialty (yellow),
prospective ESVM members (orange).
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(a) a specialty has to be accepted in more than 2/5th of EU
countries, or (b) a compelling case of specialty need, not
covered by existing ones, has to be demonstrated. In addi-
tion to the compelling medical need, the essential formal
requirements to integrate vascular medicine in the EU
directive requires coordination and set up of minimal train-
ing standards. Importantly, these training standards were
recently developed by the Division of Vascular Medicine
of the Union Européenne des Médecins Spécialistes
(UEMS, European Union of Medical Specialists) [9], and
ESVM (vascular-medicine.org) for diagnostic and non-
invasive angiology training, and interventional therapy,
respectively. Furthermore, standards and accreditation of
European training centres are also being organized and
vascular physicians may obtain a European Diploma of
Vascular Medicine [9]. These standards can already be
adopted in countries without formal recognition of vascular
medicine aiming at improving inequality in care for
patients with vascular disease.
The way forward
To move forward in the struggle to deal with multimorbid
poly-vascular patients, it is essential to establish medical
vascular medicine programs in Europe and worldwide.
Additionally, key steps include improving public awareness
of vascular diseases, and increasing the visibility of the
importance of integrated vascular care of our patients. To
achieve this goal, it is of utmost importance to attain formal
recognition by the EU of angiology/vascular medicine as a
specialty by presenting a compelling case and creating spe-
cialized treatment guidelines (e.g. [6]). We believe these
fundamental steps will encourage most European countries
to recognize vascular medicine as a specialty and will
prompt other specialties to join efforts in developing vascu-
lar awareness and management not only in Europe but
worldwide. Through this ‘position paper’ we hope to draw
attention to the plight of the vascular patient and ask for
support in our endeavours to improve their care.
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